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Abbreviations {#nc005}
=============

CI

:   Confidence Interval

HF

:   Heart Failure

HR

:   Hazard ratio

1. Introduction {#s0005}
===============

Heart failure (HF) is a very common cardiovascular disease and one of the leading causes of hospitalization and mortality worldwide, especially in older adults [@b0005], [@b0010]. The mortality rate from HF has been decreasing significantly in past few decades due to the implementation of beta-blockers, renin-angiotensin-aldosterone system blockers, coronary revascularization, implantable cardioverter-defibrillator, and cardiac resynchronization therapies [@b0015]. However, the mortality rate remained high with 5-year mortality up to 42.3% in patients hospitalized for HF [@b0020]. Identifying clinical prognosticating factors in such patients is among foci of clinical research. Several factors have been found associated with a worse cardiovascular outcome and an increased mortality in patients with HF. These factors include, but not limited to, increased resting heart rate, low ejection fraction, raised creatinine, New York Heart Association Class III/IV, history of left bundle branch block, low systolic blood pressure, and older age [@b0025].

Cognitive dysfunction is a common condition in patients with HF. A systematic review including 4176 participants in 26 cohorts revealed the prevalence of cognitive impairment at 43% in patients with HF [@b0030]. Among such patients, cognitive dysfunction has been found associated with poorer medical adherence [@b0035], lower ability for self-care [@b0040], lower disease awareness [@b0045], increased hospitalization [@b0050], and higher cardiovascular events [@b0055].

Several studies have been conducted to study the impact of cognitive impairment on mortality in patients with HF [@b0060], [@b0065], [@b0070], [@b0075], [@b0080], [@b0085], [@b0090]. However, there has been no systematic review or meta-analysis to confirm this relation. This is the first meta-analysis to evaluate the association between cognitive impairment and long-term mortality in patients with HF.

2. Methods {#s0010}
==========

2.1. Search strategy {#s0015}
--------------------

Two investigators (NP and CK) independently searched for published studies indexed in MEDLINE and EMBASE databases from inception to October 2018 using a search strategy that included the terms "cognitive impairment", "cognitive dysfunction", "heart failure", and "mortality". Publications in only English language were included. A manual search for additional pertinent studies and review articles using references from retrieved articles was also completed.

2.2. Inclusion criteria {#s0020}
-----------------------

The eligibility criteria included the following:(1)Cohort studies (prospective or retrospective) or randomized controlled trials of HF patients with and without cognitive impairment that compared all-cause mortality rate between the two populations.(2)Relative risk, hazard ratio (HR), odds ratio, incidence ratio, or standardized incidence ratio with 95% confidence intervals (CIs) or sufficient raw data for these calculations had to be provided.

Study eligibility was independently determined by two investigators (NP and CK) and differences were resolved by mutual consensus. Newcastle--Ottawa quality assessment scale, ranging from 0 to 9, was used to evaluate each cohort study in three domains: recruitment and selection of the participants, similarity and comparability between the groups, and ascertainment of the outcome of interest among cohort studies [@b0095]. Cochrane Collaboration tool for assessing risk of bias was used to evaluate the quality of each randomized controlled trial [@b0100].

2.3. Data extraction {#s0025}
--------------------

A standardized data collection form was used to obtain the following information from each study: name of first author, year of the study, country of origin, study type, inclusion and exclusion criteria, number and demographic data of the participants, duration of follow-up, diagnostic method of HF, mortality rate, assessment tools used to identify cognitive impairment, adjusted confounders and conclusion by authors.

To ensure accuracy, two investigators (NP and CK) independently performed this data extraction process. Should there be any data discrepancy, we referred back to the original articles.

2.4. Definition {#s0030}
---------------

HF was diagnosed differently as defined in each study ([Table 1](#t0005){ref-type="table"}). Cognitive impairment was defined as an abnormality of at least one of the five domains of the cognitive function [@b0105] or as defined in each study ([Table 1](#t0005){ref-type="table"}). Mortality was defined by all-cause mortality during the follow-up period.Table 1Study characteristics.First authorYearCountryStudy typeInclusion criteriaExclusion criteriaMean age (SD)Male (%)Follow-up (months)Total participants (*n*)HF diagnostic methodMortality rate (%)CI screening method and diagnosisPatients with CI (%)Confounder adjustmentConclusionGonz2014SpainRandomized controlled trialIndividuals diagnosed with acute HF and discharged from Geriatric Service of the Caceres Hospital complexN/A85 (N/A)2712116According to the European Society of Cardiology Guidelines 200830.1GDS ≥319.8N/AParticipants without CI in disease management program had lower probability of CV event. This effect was not seen in the CI groupHuijts2013NetherlandRetrospective cohortHF patients age ≥60 years old with HF, history of HF hospitalization within the past year, NT-proBNP higher than twice the upper limit of normalDyspnea not mainly from HF, valvular heart disease, short life expectancy, recent angina, history of revascularization76 (8)61.318382Signs and symptoms of HF or currently NYHA class ≥2 and on HF therapyN/AAMT ≤79.2N/ACI is often unrecognized in HF patients, but the influence of HF severity and its changes on cognitive function were less than hypothesizedLan2018USARetrospective cohortOutpatient veterans with a clinical diagnosis of HF without previous history of CILife expectancy of less than 6 months or documented dementia requiring a caregiver66.4 (N/A)98.836250N/A25.6SLUMS \<2557.6Demographics data, comorbidity, LVEF, SLUMS scoreCI was an independent risk factor for mortality in patients with HF.McLennan2006AustraliaRandomized controlled trialHF patients with EF ≤55% and NYHA ≥2Malignancy, documented dementia, unable to be discharged to their own home75.6 (8)60.160200Diagnosed by confirmed LVEF \<55% and NYHA ≥296.3MMSE ≤2613.5N/AMild CI is of prognostic importance in CHFMurad2015USAProspective cohortParticipants from the Cardiovascular Health Study who developed HFN/A79.2 (6.3)51.8120558Clinical diagnosis made by a treating physician, and being on medications for HF including both a diuretic and either a digitalis preparation or a vasodilator833MSE \<8017.4Demographic data, functional impairmentSome of comorbidities in elderly with incident HF are associated with greater mortality riskDel Sindaco2012ItalyRetrospective cohortHF patients \>70 years old with NYHA ≥3Valvular heart disease, active substance abuse, psychiatric illness, dementia, short life expectancy, non-consent patient, living in nursing care77 (4.6)52.024173Diagnosis was determined according to the European Society of Cardiology Guidelines 200131.4MMSE ≤2441.6Demographic data, comorbidityCI is very common and associated with worse prognosis in HF patientsSokoreli2018UKProspective observational studyHF patients \>18 years old, live in the region served by the Hull and East Yorkshire hospitals NHS trust and hospitalized for HF and on treatment with loop diureticsUnable to understand and comply with the protocol. Unable or unwilling to give informed consent.76 (15)6612671At least one of the following:\
LVEF ≤40%, left atrial dimension \>4.0 cm, 8 or NT-proBNP \>400/1200 pg/mL for sinus rhythm/atrial fibrillation15.6GPCOG ≤446.9Demographic data, comorbidity, LVEF, HADS, serum urea and creatininePsychological factors are strongly associated with unplanned recurrent readmissions or mortality following an admission for HFZucala2003ItalyRetrospective cohortPatients admitted with principal diagnosis of HFNone78 (9)53.912968Clinically diagnosed by the study researchers16AMT \<724.6Demographic data, comorbidity, medicationCI is an independent prognostic marker in older patients with HF[^1]

2.5. Statistical analysis {#s0035}
-------------------------

The meta-analysis was performed using a random-effects model. The extracted studies were excluded from the analysis if they did not justify an outcome in each cohort. We pooled the point estimates from each study using the generic inverse-variance method of Der Simonian and Laird [@b0110]. The heterogeneity of effect size estimates across these studies was measured using the I^2^ statistic. The I^2^ statistic ranges in value from 0% to 100% (I^2^ \< 25%, low heterogeneity; I^2^ = 25--50%, moderate heterogeneity; I^2^ \> 50%, substantial heterogeneity). A sensitivity analysis was also conducted. Publication bias was assessed using a funnel plot and Egger's regression test (*p* \< 0.05 was considered significant). All data analyses were performed using the StataCorp 2015, Stata: Release 14, Statistical Software (StataCorp LP, College Station, TX).

3. Results {#s0040}
==========

3.1. Study inclusion and characteristic {#s0045}
---------------------------------------

In total, 303 potentially relevant studies (full articles) conducted were identified (88 studies from EMBASE, 215 studies from PUBMED). After exclusion of 72 duplicate studies, 231 studies underwent title and abstract review. After the initial reviewed, 198 studies were excluded as they were not conducted in HF patients with cognitive impairment, and 33 studies underwent full-article review. A further 25 studies were excluded as they did not have a control group and/or did not report all-cause mortality rate and/or did not have a clear definition of cognitive impairment. Therefore, eight eligible studies with a total of 3318 participants (951 participants had cognitive impairment) were included for meta-analysis. The PRISMA diagram flow is demonstrated in [Fig. 1](#f0005){ref-type="fig"}. Mortality rate was compared between HF patients with and without cognitive impairment. The prevalence of cognitive impairment ranged from 9.2% to 57.6% across the included studies. Characteristics of the included studies in the meta-analysis are summarized in [Table 1](#t0005){ref-type="table"}.Figure 1PRISMA flow diagram demonstrating search strategy and selection process.

3.2. Quality of eligible studies {#s0050}
--------------------------------

The quality of the included cohort studies and randomized controlled trials were evaluated by the Newcastle--Ottawa Scale and the Cochrane Collaboration tool for assessing risk of bias, respectively ([Supplementary file 2 and 3](#s0100){ref-type="sec"}).

3.3. Quantitative analyses {#s0055}
--------------------------

In random-effect model, our analysis showed that the presence of cognitive impairment significantly increased the risk of mortality in HF patients with pooled HR of 1.64 (95% CIs: 1.42, 1.88, I^2^ = 0.0%, *p* \< 0.001; [Fig. 2](#f0010){ref-type="fig"}).Figure. 2Forest plot of included studies assessing the association between cognitive impairment and mortality rate in patients with heart failure. CI = confidence interval; HR = hazard ratio.

3.4. Sensitivity analysis {#s0060}
-------------------------

We assessed the stability of the meta-analysis results. We conducted a sensitivity analysis by excluding one study at a time. None of the results were significantly altered, as the results after removing one study at a time were consistent with the main meta-analysis. This indicated that our results were robust.

3.5. Publication bias {#s0065}
---------------------

Funnel plot and Egger's test were performed to confirm absent of publication bias. The funnel plot ([Fig. 3](#f0015){ref-type="fig"}) was symmetric indicating no publication bias, and Egger's test reported no small studies effect (95% CI: --0.91, 3.93, *p* = 0.179; [Fig. 4](#f0020){ref-type="fig"}).Figure. 3Funnel plot of cognitive impairment and mortality. Circles represent published studies. HR = hazard ratio.Figure. 4Egger's test. CI = confidence interval, SND = Standardized.

4. Discussion {#s0070}
=============

To the best of our knowledge, this is the first meta-analysis examining the association between cognitive impairment and mortality in the HF population. Our meta-analysis showed a 1.64-fold increase in mortality rate among HF patients with cognitive impairment compared with that among those without cognitive impairment.

Huijts et al. [@b0065] reported the lowest cognitive impairment prevalence at 9.2%, whereas the study by Lan et al. [@b0070] showed the highest cognitive impairment prevalence at 57.6%. This major difference was likely due to a variation in participants' demographic and screening instruments. Every included study reported a significant association between the presence of cognitive impairment and an increased mortality rate in HF patients. Despite the highest reported cognitive impairment prevalence in the study by Lan et al. [@b0070], the highest mortality rate was found in the study by McLennan et al. [@b0075] (96.3%), which followed patients up to 60 months. The study by Murad et al. [@b0085] had the longest follow-up duration (120 months) and reported the relatively high mortality rate of 83%. The study by Zuccala et al. [@b0090], which had the highest number of participants (*n* = 968), reported the cognitive impairment prevalence and mortality rate at 24.6% and 16%, respectively.

Although the differences in study characteristics were obvious, the low level of heterogeneity among studies is particularly interesting suggesting that the effect of cognitive impairment on mortality is consistent despite the variation in demographics, screening tools, and follow-up duration. As there is still not enough evidence regarding the most sensitive and specific method and the optimal timing for cognitive screening in HF population [@b0115], this could imply that different instrument may be equally effective in screening for cognitive impairment, and the diverse cognitive impairment prevalence was mainly from the difference in participants' demographics. Moreover, the effect of cognitive impairment on mortality could be similar on both short- and long-term follow-up. Nevertheless, this further strengthens the result of our meta-analysis and confirms the existence of this relation.

Recent evidence from a systematic review and meta-analysis found a significant association between cognitive impairment and HF [@b0030]. Several mechanisms have been suggested to explain this finding. One is the low systolic blood pressure found to be associated with the presence of cognitive impairment in the HF population [@b0120]. In addition to cardiogenic emboli and other comorbidities, this leads to chronic poor cerebral perfusion and progressive degeneration of the brain [@b0125]. Some factors, such as anemia, chronic kidney disease, older age, and lower left ventricular ejection fraction, were also found relating to the presence of cognitive impairment in HF patients [@b0130], [@b0135], [@b0140]. Despite the recommendation to screen for cognitive impairment in HF patients, the dysfunction of cognition in the majority of HF patients was still undetected [@b0145]. One study revealed that by the time of discharge, as little as 23% of HF patients with impaired cognition had it documented [@b0150].

Management of cognitive impairment in HF is still in debate. Patients with cognitive impairment were found to have less effective self-care and medical non-compliance [@b0155], [@b0160], [@b0165]. However, there is no data showing that improving HF knowledge or lifestyle could reduce cardiovascular outcome in the HF population with cognitive impairment. Currently, delaying the progression of cognitive impairment by targeting comorbidities, such as hypertension, atrial fibrillation and depression seem to be beneficial [@b0170]. More research is needed to explore an effective intervention in reducing cardiovascular outcome in HF patients with cognitive impairment.

4.1. Strengths and limitations {#s0075}
------------------------------

The strength of this meta-analysis is that most studies were prospective studies. The result from our analysis showed heterogeneity of 0.0%, which demonstrated the consistency of the results among the included studies.

We also found limitations. First, the included studies did not report the type or classification of the HF. Secondly, HRs from the study by Gonz et al. [@b9000], Huijts et al. [@b0065], and Zuccala et al. [@b0090] were not adjusted for other variables, and outcome from the study by Sokoleri et al. [@b9005] also included re-hospitalization rate. However, subgroup analysis without the four studies still showed a significant association between cognitive impairment and mortality in HF patients ([Fig. 5](#f0025){ref-type="fig"}). Lastly, each study used different cognitive screening tools and had various follow-up durations. Nevertheless, the absence of heterogeneity implied that each study reported comparable HR and could be combined for meta-analysis.Figure. 5Subgroup analysis of studies with adjusted hazard ratio of cognitive impairment and mortality rate in patients with heart failure. CI = confidence interval.

5. Conclusions {#s0080}
==============

In conclusion, our systematic review and meta-analysis showed that the presence of cognitive impairment is strongly associated with an increased mortality rate among patients with HF. This emphasizes the necessity for cognitive assessment among HF population. Further research is needed to explore the pathophysiology and to appropriately manage the dysfunction of cognition in this population.
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[^1]: 3MSE = modified mini-mental state exam; AMT = Hodkinson abbreviated mental test; CI = cognitive impairment; CV = cardiovascular; GDS = global deterioration scale; GPCOG = general practitioner assessment of cognition; HADS = hospital anxiety and depression scale; HF = heart failure; LVEF = left ventricular ejection fraction; MMSE = mini-mental state examination; N/A = not available; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart American Classification; SLUMS = The Saint Louis University Mental Status.
